- Wearable wellness technology innovator MetAlert is revitalizing its brand and increasing its product and services portfolio through M&A and other corporate developments designed to improve the company’s healthcare profile
- The mortality associated with chronic disease can be ameliorated with the use of wearable devices, along with other healthful practices, and the use of wearable wellness technology is expected to continue at an increasing pace
- More than 41 million people die of noncommunicable diseases (aka chronic illnesses) each year — 17 million of them before the age of 70, according to the World Health Organization
- MetAlert’s growing product slate is designed to combine unobtrusive wearability, tracking technology, telehealth communication capabilities, and artificial intelligence, to serve the needs of patients and caregivers
For many people, the beginning of a new year signals a time to renew efforts at self-betterment through increased exercise and other healthful practices. One means of measuring improvements that has become popular in recent years is the use of a pedometer to track the wnumber of the wearer’s “steps” in a given day, and smartwatches have made such wearable devices unobtrusive and easily accessible (https://ibn.fm/rs2hb).
The modern variety in wearable technologies has gained increasing use in part because the devices may enable individuals to self-assess their goals and conditioning without the need to visit to visit medical clinics to obtain physiological data and analyze it for biomedicine, healthcare and wellness purposes.
Big data analyst PatSnap reports more than 722 million wearable devices were in use worldwide in 2019 and that they are expected to reach one billion by the end of this year, calling wearable devices “the new healthcare revolution”, and anticipating that the wearable technology industry will see a CAGR of 13.67 percent between this year and 2027 (https://ibn.fm/z9Zwa).
Location-sensitive health monitoring wearable device developer MetAlert (OTC: MLRT) is building its product portfolio and profile of affiliated companies, working to become a market leader in the wearable technology industry.
The company’s patented GPS SmartSole shoe insoles have become its flagship offering in delivering a solution for those at risk of wandering or becoming lost or disoriented due to Alzheimer’s disease and other dementias, autism, or traumatic brain injury, and MetAlert is expanding its sights with products that may help protect fall-prone patients and grant them confidence-building independence, as well as small tracking devices with increased battery life and products that provide telehealth connectivity and assessment tools.
According to the World Health Organization (“WHO”), noncommunicable diseases (NCDs, also known as chronic illnesses) claim the lives of some 41 million people each year — 17 million annually before they reach the age of 70. The agency notes physical fitness, good eating habits, safe alcohol use and tobacco avoidance are all important in improving a patient’s potential to avoid dying from an NCD (https://ibn.fm/N50kM).
An increase in attention to lifestyle wellness factors is expected to continue raising the overall age of the world’s elderly population, but with increasing age the prevalence of chronic diseases such as dementia, heart disease, and diabetes increases as well, indicating the market potential for wearable devices that may help patients cope with their conditions as successfully as possible.
“Strategic acquisitions, expanding our products and services, and increasing our revenues per user (‘RPU’), should help set us on a path toward continued success in the coming months and years”, MetAlert CEO and Founder Patrick Bertagna stated in a Jan. 5 letter to the company’s shareholders (https://ibn.fm/tAkQF). “Moreover, aligning with new technologies could open possibilities for crucial data analysis that has the potential to revolutionize how we conduct and manage healthcare worldwide.”
For more information, visit the company’s website at www.MetAlert.com.
NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
BioMedWire is part of the InvestorBrandNetwork.